Masatoshi Kudo

Last updated: Jun 28, 2016 at 11:29
 
Avatar
Name
Masatoshi Kudo
Nickname
Masatoshi Kudo
E-mail
m-kudomed.kindai.ac.jp
Affiliation
Kindai University
Section
Faculty of Medicine
Research funding number
10298953

Research Areas

 
 

Published Papers

 
Response
Kitano M, Imai H, Kamata K, Kudo M
Gastrointest Endosc   83 1303   2016   [Refereed]
Modified single transluminal gateway transcystic multiple drainage technique for a huge infected walled-off pancreatic necrosis: A case report
Minaga K, Kitano M, Imai H, Yamao K, Kamata K, Miyata T, Matsuda T, Omoto S, Kadosaka K, Yoshikawa T, Kudo M
walled-off pancreatic necrosis: A case report.   22 5132-5136   2016   [Refereed]
TACE treatment in patients with sorafenib-treated unresectable hepatocellular carcinoma in clinical practice: final analysis of GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib)
Geschwind JF, Kudo M, Marrero JA, Venook AP, Chen XP, Bronowicki JP, Dagher L, Furuse J, de Guevara LL, Papandreou C, Sanyal AJ, Takayama T, Ye SL, Yoon SK, Nakajima K, Lehr R, Heldner S, Lencioni R
Radiology   279 630-640   2016   [Refereed]
Histologic diagnosis of pancreatic masses using 25-gauge endoscopic ultrasound needles with and without a core trap: a multicenter randomized trial
Kamata K, Kitano M, Yasukawa S, Kudo M, Chiba Y, Ogura T, Higuchi K, Fukutake N, Ashida R, Yamasaki T, Nebiki H, Hirose S, Hoki N, Asada M, Yazumi S, Takaoka M, Okazaki K, Matsuda F, Okabe Y, Yanagisawa A
Endoscopy   48 1-7   2016   [Refereed]
Contrast-enhanced harmonic endoscopic ultrasonography for assessment of lymph node metastases in pancreatobiliary carcinoma
Miyata T, Kitano M, Omoto S, Kadosaka K, Kamata K, Imai H, Sakamoto H, Nishida N, Harwani Y, Murakami T, Takeyamas Y, Chiba Y, Kudo M
World J Gastroenterol   22 3381-3391   2016   [Refereed]
Heterogeneity and subclassification of Barcelona Clinic Liver Cancer Stage B
Masatoshi Kudo
Liver Cancer   5 91-96   2016   [Refereed][Invited]
Kupffer phase image of Sonazoiod-enhanced US is useful in predicting a hypervascularization of non-hypervascular hypointense hepatic lesions detected on Gd-EOB-DTPA-enhanced MRI: A multicenter retrospective study
Inoue T, Hyodo T, Korenaga K, Murakami T, Imai Y, Higaki A, Suda T, Takano T, Miyoshi K, Koda M, Tanaka H, Iijima H, Ochi H, Hirooka M, Numata K,Kudo M
J Gastroenterol   51 144-152   2016   [Refereed]
Response evaluation criteria in cancer of the liver (RECICL)(2015 revised version)
Kudo M, Ueshima K, Kubo S, Sakamoto M, Tanaka M, Ikai I, Furuse J, Murakami T, Kadoya M, Kokudo N, Liver Cancer Study Group of Japan
Hepatol Res   46 3-9   2016   [Refereed]
Multicenter cooperative case survey of hepatitis B Virus reactivation by chemotherapeutic agents
Takahashi H, Ikeda M, Kumada T, Osaki Y, Kondo S, Kusumoto S, Ohkawa K, Nadano S, Furuse J, Kudo M, Ito K, Yokoyama M, Okusaka T, Shimoyama M, Mizokami M
Hepatol Res   45 1220-1227   2015   [Refereed]
Synchronous pancreatic and gastric metastasis from an ovarian adenocarcinoma diagnosed by endoscopic ultrasound-guided fine-needle aspiration
Yamao K, Kitano M, Kudo M, Maenishi O
Endoscopy   47 596-597   2015   [Refereed]
Antiviral therapy for chronic hepatitis B: combination of nucleoside analogs and interferon
Hagiwara S, Nishida N, Kudo M
World J Hepatol   7 2427-2431   2015   [Refereed]
Recent advances in the management of chronic hepatitis B including suppression of hepatocellular carcinoma by entecavir and interferon
Kim SK, Kim SR, Imoto S, Tohyama M, Otono Y, Tamura T, Kim KI, Kobayashi M, Ohtani A, Sugimoto K, Mizuguchi A, Hiramatsu Y, Kudo M
Oncology   89 60-69   2015   [Refereed]
A newly developed shear wave elastography modality: with a unique reliability index
Yada N, Sakurai T, Minami T, Arizumi T, Takita M, Hagiwara S, Ueshima K, Ida H, Nishida N, Kudo M
Oncology   89 53-59   2015   [Refereed]
Validation of a modified substaging system (Kinki Criteria) for patients with intermediate-stage hepatocellular carcinoma
Arizumi T, Ueshima K, Iwanishi M, Minami T, Chishina H, Kono M, Takita M, Kitai S, Inoue T, Yada N, Hagiwara S, Ida H, Minami Y, Sakurai T, Kitano M, Nishida N, Kudo M
Oncology   89 47-52   2015   [Refereed]
Comparison of daclatasvir and asunaprevir for chronic HCV 1b infection with telaprevir and simeprevir plus peginterferon and ribavirin, with a focus on the prevention of occurrence and recurrence of hepatocellular carcinoma
Sugimoto K, Kim SR, Kim SK, Imoto S, Tohyama M, Kim KI, Ohtani A, Hatae T, Yano Y, Kudo M, Hayashi Y
Oncology   89 42-46   2015   [Refereed]
Hyperenhanced rim surrounding liver metastatic tumors in the postvascular phase of sonazoid-enhanced ultrasonography: a histological indication of the presence of Kupffer cells
Tochio H, Sugahara M, Imai Y, Tei H, Suginoshita Y, Iwasaki N, Sasaki I, Hamada M, Minowa K, Inokuma T, Kudo M
Oncology   89 33-41   2015   [Refereed]
Balloon-occluded transcatheter arterial chemoembolization for hepatocellular carcinoma: a single-center experience
Minami Y, Minami T, Chishina H, Arizumi T, Takita M, Kitai S, Yada N, Hagiwara S, Tsurusaki M, Yagyu Y, Ueshima K, Nishida N, Murakami T, Kudo M
Oncology   89 27-32   2015   [Refereed]
Percutaneous radiofrequency ablation for Intermediate-stage hepatocellular carcinoma
Kariyama K, Wakuta A, Nishimura M, Kishida M, Oonishi A, Ohyama A, Nouso K, Kudo M
Oncology   89 19-26   2015   [Refereed]
Initial experience performing percutaneous ultrasound examination with real-time virtual sonography with color display
Ogawa C, Minami Y, Noda T, Arasawa S, Izuta M, Kubo A, Matsunaka T, Tamaki H, Shibatoge M, Kudo M
Oncology   89 11-18   2015   [Refereed]
Evaluation of ART scores for repeated transarterial chemoembolization in Japanese patients with hepatocellular carcinoma
Arizumi T, Ueshima K, Iwanishi M, Minami T, Chishina H, Kono M, Takita M, Kitai S, Inoue T, Yada N, Hagiwara S, Ida H, Minami Y, Sakurai T, Nishida N, Kitano M, Kudo M
Oncology   89 4-10   2015   [Refereed]
Evidence and consensus on management of hepatocellular carcinoma: update in 2015
Masatoshi Kudo
Oncology   89 1-3   2015   [Refereed][Invited]
Molecular mechanism and prediction of sorafenib chemoresistance in human hepatocellular carcinoma
Nishida N, Kitano M, Sakurai T, Kudo M
Digest Dis   33 771-779   2015   [Refereed]
General rules for the clinical and pathological study of primary liver cancer, nationwide follow-up survey and clinical practice guidelines: the outstanding achievements of the Liver Cancer Study Group of Japan
Kudo M*, Kitano M, Sakurai T, Nishida N
Digest Dis   33 765-770   2015   [Refereed]
Cone-beam CT angiography for hepatocellular carcinoma: current status
Minami Y, Murakami T, Kitano M, Sakurai T, Nishida N, Kudo M
Digest Dis   33 759-764   2015   [Refereed]
Subclassification of BCLC stage hepatocellular carcinoma and treatment strategies: Proposal of modified Bolondi subclassification (Kinki Criteria)
Kudo M*, Arizumi T, Ueshima K, Sakurai T, Kitano M, Nishida N
Digest Dis   33 751-758   2015   [Refereed]
Hepatic DNA methylation is affected by hepatocellular carcinoma risk in patients with and without hepatitis virus
Nishida N, Iwanishi M, Minami T, Chishina H, Arizumi T, Takita M, Kitai S, Yada N, Ida H, Hagiwara S, Minami Y, Ueshima K, Sakurai T, Kitano M, Kudo M
Digest Dis   33 745-750   2015   [Refereed]
Real-life clinical practice with sorafenib in advanced hepatocellular carcinoma: a single-center experience second analysis
Arizumi T, Ueshima K, Iwanishi M, Chishina H, Kono M, Takita M, Kitai S, Inoue T, Yada N, Hagiwara S, Ida H, Minami Y, Sakurai T, Nishida N, Kitano M, Kudo M
Digest Dis   33 728-734   2015   [Refereed]
Characteristics of hypovascular versus hypervascular well-differentiated hepatocellular carcinoma smaller than 2cm - focus on tumor size, markers and imaging detectability
Sugimoto K, Kim SR, Imoto S, Tohyama M, Kim SK, Matsuoka T, Yano Y, Kudo M, Hayashi Y
Digest Dis   33 721-727   2015   [Refereed]
Usefulness of cytokeratin-18M65 in diagnosing non-alcoholic steatohepatitis in Japanese population
Hasegawa Y, Kim SR, Hatae T, Ohta M, Fujinami A, Sugimoto K, Kim KI, Imoto S, Tohyama M, Kim SK, Ikura Y, Kudo M
Digest Dis   33 715-720   2015   [Refereed]
Early viral response predicts the efficacy of antiviral triple therapy with simeprevir, peg-interferon, and ribavirin in patients infected with hepatitis C virus genotype 1
Nishida N, Iwanishi M, Minami T, Chishina H, Arizumi T, Takita M, Kitai S, Yada N, Ida H, Hagiwara S, Minami Y, Ueshima K, Sakurai T, Kitano M, Kudo M
Digest Dis   33 708-714   2015   [Refereed]
Chronic Liver Diseases and Liver Cancer: An Update in 2015
Masatoshi Kudo
Digest Dis   33 705-707   2015   [Refereed]
Validation of the hepatoma arterial embolisation prognostic score in European and Asian populations and proposed modification
Pinato DJ, Arizumi T, Allara E, Jang JW, Smirne C, Kim YW, Kudo M, Pirisi M, Sharma R
Clin Gastroenterol H   13 1204-1208   2015   [Refereed]
Evidence-based clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2013 update (3rd JSH-HCC Guidelines)
Kokudo N, Hasegawa K, Akahane M, Igaki H, Izumi N, Ichida T, Uemoto S, Kaneko S, Kawasaki S, Ku Y, Kudo M, Kubo S, Takayama T, Tateishi R, Fukuda T, Matsui O, Matsuyama Y, Murakami T, Arii S, Okazaki M, Makuuchi M
Hepatol Res   45 123-127   2015   [Refereed]
Heat shock protein A4 controls cell migration and gastric ulcer healing
Sakurai T, Kashida H, Hagiwara S, Nishida N, Watanabe T, Fujita J, Kudo M
Digest Dis Sci   60 850-857   2015   [Refereed]
The role of hepatic resection in the treatment of hepatocellular cancer
Roayaie S, Jibara G, Tabrizian P, Park JW, Yang J, Yan L, Schwartz M, Han G, Izzo F, Chen M, Blanc JF, Johnson P, Kudo M, Roberts L, Sherman M
Hepatology   62 440-451   2015   [Refereed]
Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE study
Park JW, Chen M, Colombo M, Roberts LR, Schwartz M, Chen PJ, Kudo M, Johnson P, Wagner S, Orsini LS, Sherman M
Liver Int   35 2155-2166   2015   [Refereed]
Value of dynamic contrast enhanced MRI in predicting outcomes of HCC receiving radiotherapy
Masatoshi Kudo
Hepatol Int   9 155-156   2015   [Refereed]
Safety and efficacy of tigatuzumab plus sorafenib as first-line therapy in subjects with advanced hepatocellular carcinoma: a phase 2 randomized study
Cheng AL, Kang YK, He AR, Lim HY, Ryoo BY, Hung CH, Sheen IS, Izumi N, Austin T, Wang Q, Greenberg J, Shiratori S, Beckman RA, Kudo M and the investigators’study group
J Hepatol   63 896-904   2015   [Refereed]
Primary leiomyosarcoma of the colon
Kono M, Tsuji N, Ozaki N, Matsumoto N, Takaba T, Okumura N, Kawasaki M, Tomita T, Umehara Y, Taniike S, Hatabe S, Funai S, Ono Y, Ochiai K, Maekura S, Kudo M
Clin J Gastroenterol   8 217-222   2015   [Refereed]
Plasmacytoid dendritic cell activation and IFN-α production are prominent features of murine autoimmune pancreatitis and human lgG4-related autoimmune panreatitis
Arai Y, Yamashita K, Kuriyama K, Shiokawa M, Kodama Y, Sakurai T, Mizugishi K, Uchida K, Kadowaki N, Takaori-Kondo A, Kudo M, Okazaki K, Strober W, Chiba T, Watanabe T
J Immunol   195 3033-3044   2015   [Refereed]
Peretinoin after curative therapy of hepatitits C-related hepatocellular carcinoma: a randomized double-blind placebo-controlled study
Okita K, Izumi N, Matsui O, Tanaka K, Kaneko S, Moriwaki H, Ikeda K, Osaki Y, Numata K, Nakachi K, Kokudo N, Imanaka K, Nishiguchi S, Okusaka T, Nishigaki Y, Shiomi S, Kudo M, Ido K, Karino Y, Hayashi N, Ohashi Y, Makuuchi M, Kumada H, Peretinoin Study Group
J Gastroenterol   50 191-202   2015   [Refereed]
WFUMB guidelines and recommendations for clinical use of ultrasound elastography: Part 2; Breast
Barr R, Nakashima K, Amy D, Cosgrove D, Farrokh A, Schafer F, Bamber J, Castera L, Choi B, Chou Y, Dietrich C, Ding H, Ferraioli G, Filice C, Friedrich-Rust M, Hall T, Nightingale K, Palmeri M, Shiina T, Suzuki S, Sporea I, Wilson S, Kudo M
Ultrasound Med Biol   41 1148-1160   2015   [Refereed]
WFUMB guidelines and recommendations for clinical use of ultrasound elastography: Part3; Liver
Ferraioli G, Filice C, Castera L, Choi B, Sporea I, Wilson S, Cosgrove D, Dietrich C, Amy D, Bamber J, Barr R, Chou Y, Ding H, Farrokh A, Friedrich-Rust M, Hall T, Nakashima K, Nightingale K, Palmeri M, Schafer F, Shiina T, Suzuki S, Kudo M
Ultrasound Med Biol   41 1161-1179   2015   [Refereed]
Foreword to the WFUMB guideline and recommendations on the clinical use of ultrasound elastography
Masatoshi Kudo
Ultrasound Med Biol   41 1125   2015   [Refereed]
WFUMB guidelines and recommendations for clinical use of ultrasound elastography: Part 1; basic principles and terminology
Shiina T, Nightingale K, Palmeri M, Hall T, Bamber J, Barr R, Castera L, Choi B, Chou Y, Cosgrove D, Dietrich C, Ding H, Amy D, Farrokh A, Ferraioli G, Filice C, Friedrich-Rust M, Nakashima K, Schafer F, Sporea I, Suzuki S, Wilson S, Kudo M
Ultrasound Med Biol   41 1126-1147   2015   [Refereed]
Survey of survival among patients with hepatitis C virus-related hepatocellular carcinoma treated with peretinoin, an acyclic retinoid, after the completion of a randomized placebo-controlled trial
Okita K, Izumi N, Ikeda K, Osaki Y, Numata K, Ikeda M, Kokudo N, Imanaka K, Nishiguchi S, Kondo S, Nishigaki Y, Shiomi S, Ueshima K, Isoda N, Karino Y, Kudo M, Tanaka K, Kaneko S, Moriwaki H, Makuuchi M, Okusaka T, Hayashi N, Ohashi Y, Kumada H, and Peretinoin Study Group
J Gastroenterol   50 667-674   2015   [Refereed]
Contrast-enhanced harmonic endoscopic ultrasonography for pancreatobiliaty diseases
Kitano M, Kamata K, Imai H, Miyata T, Yasukawa S, Yanagisawa A, Kudo M
Digest Endosc   27 60-67   2015   [Refereed]
A bridge between multi-omics data and the management of hepatocellular carcinoma
Nishida N, Kudo M
Ann Transl Med   3 1   2015   [Refereed]
Percutaneous endoscopic gastrostomy with Funada-style gastropexy greatly reduces the risk of peristomal infection
Okumura N, Tsuji N, Ozaki N, Matsumoto N, Takaba T, Kawasaki M, Tomita T, Umehara Y, Taniike S, Kono M, Kudo M
Gastroenterol Rep   3 69-74   2015   [Refereed]
Linifanib versus sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial
Cainap C, Qin S, Huang WT, Chung IJ, Pan H, Cheng Y, Kudo M, Kang YK, Chen PJ, Toh HC, Gorbunova V, Eskens FA, Qian J, McKee MD, Ricker JL, Carlson DM, Nowiem SE
J Clin Oncol   33 172-179   2015   [Refereed]
Stabilization technique for real-time high-resolution vascular ultrasound using frequency domain interferometry
Taki H, Taki K, Yamakawa M, Shiina T, Kudo M, Sato T
Conf Proc IEEE Eng Med Biol Soc   5085-5088   2014   [Refereed]
Malignant transformation of hepatocellular adenoma: How frequently does it happen?
Masatoshi Kudo
Liver Cancer   1 1-5   2015   [Refereed]
Involvement of heat shock protein A4/Apg-2 in refractory inflammatory bowel disease
Adachi T, Sakurai T, Kashida H, Mine H, Hagiwara S, Matsui S, Yoshida K, Nishida N, Watanabe T, Itoh K, Fujita J, Kudo M
Inflamm Bowel Dis   21 31-39   2015   [Refereed]
Prospective Multicenter Randomized Controlled Trial of Histological Diagnostic Yield Comparing 25G EUS-FNA Needles With and Without a Core Trap in Patients With Solid Pancreatic Masses
Ashida R, Yasukawa S, Yanagisawa A, Kamata K, Kudo M, Ogura T, Higuchi K, Fukutake N, Nebiki H, Hirose S, Hoki N, Asada M, Yazumi S, Takaoka M, Okazaki K, Matsuda F, Okabe Y, Kitano M
Gastrointest Endosc   79 AB111   May 2014   [Refereed]
GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis
Lencioni R, Kudo M, Ye SL, Bronowicki JP, Chen XP, Dagher L, FuruseJ, Geschwind JF, de Guevara LL, Papandreou C, Takayama T, Yoon SK, Nakajima K, Lehr R, Heldner S, Sanyal AJ
Int J Clin Pract   68(5) 609-617   May 2014   [Refereed]
Tracking Navigation Imaging of Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma using Three-Dimensional Cone-Beam CT Angiography
Minami Y, Yagyu Y, Murakami T, Kudo M
Liver Cancer   3(1) 53-61   Mar 2014   [Refereed]
Therapeutic Response Assessment of RFA for HCC: Contrast-enhanced US, CT and MRI
Minami Y, Nishida N, Kudo M
World J Gastroenterol   20 4160-4166   Apr 2014   [Refereed]
Reply to Kadayifci and brugge
Kitano K, Kamata K, Kudo M
Endoscopy   46 358-358   Apr 2014
Quantitative levels of hepatitis B virus DNA and surface antigen and the risk of hepatocellular carcinoma in patients with hepatitis B receiving long-term nucleos(t)ide analogue therapy
Kawanaka M, Nishio K, Nakamura J, Oka T, Urata N, Goto D, Suehiro M, Kawamoto H, Kudo M, Yamada G
Liver Cancer   3(1) 41-52   Mar 2014   [Refereed]
Relevance of the core 70 and IL-28B polymorphism and response-guided therapy of peginterferon alfa-2a± ribavirin for chronic hepatitis C of genotype 1b: A multicenter randomized trial, ReGIT-J study
Nishiguchi S, Enomoto H, Aizawa N, Nishikawa H, Osaki Y, Tsuda Y, Higuchi K, Okazaki K, Seki T, Kim SR, Hongo Y, Jyomura H, Nishida N, Kudo M
J Gastroenterol   49 492-501   Mar 2014   [Refereed]
Re-evaluating transarterial chemoembolization for the treatment of hepatocellular carcinoma: consensus recommendations and review by an international expert panel
Cheng AL, Amarapurkar D, Chao Y, Chen PJ, Geschwind JF, Goh KL, Han KH, Kudo M, Lee HC, Lee RC, Lesmana LA, Lim HY, Paik SW, Poon RT, Tan CK, Tanwandee T, Teng G, Park JW
Liver Int   34(2) 174-183   Feb 2014   [Refereed]
Nationwide study of 4741 patients with non-B non-C hepatocellular carcinoma with special reference to the therapeutic impact.
Utsunomiya T, Shimada M, Kudo M, Ichida T, Matsui O, Izumi N, Matsuyama Y, Sakamoto M, Nakashima O, Ku Y, Kokudo N, Makuuchi M for the Liver Cancer Study Group of Japan
Ann Surg   259(2) 336-345   Feb 2014   [Refereed]
The gross classification of hepatocellular carcinoma: usefulness of contrast-enhanced US
Hatanaka K, Minami Y, Kudo M*, Inoue T, Chung H, Haji S
J Clin Ultrasound   42(1) 1-8   Jan 2014   [Refereed]
Impact of histologically confirmed lymph node metastases on the patient survival after surgical resection for hepatocellular carcinoma: report of a Japanese nationwide survey
Hasegawa K, Makuuchi M, Kokudo N, Izumi N, Ichida T, Kudo M, Ku Y, Sakamoto M, Nakashima M, Matsui O, Matsuyama Y, for the Liver Cancer Study Group of Japan
Ann Surg   259 166-170   Jan 2014   [Refereed]
Value of EUS in early detection of pancreatic ductal adenocarcinomas in patients with intraductal papillary mucinous neoplasms.
Kamata K, Kitano M, Kudo M, Sakamoto H, Kadosaka K, Miyata T, Imai H, Maekawa K, Chikugo T, Kumano M, Hyodo T, Murakami T, Chiba Y, Takeyama Y
Endoscopy   46(1) 22-29   Jan 2014
Comparison of systems for assessment of post-therapeutic response to sorafenib for hepatocellular carcinoma
Arizumi T, Ueshima K, Takeda H, Osaki Y, Takita M, Inoue T, Kitai S, Yada N, Hagiwara S, Minami Y, Sakurai T, Nishida N, Kudo M
J Gastroenterol   49 1578-1587   2014   [Refereed]
NOD2 Down-regulates colonic inflammation by IRF4-mediated inhibition of K63-linked polyubiquitination of RICK and TRAF6
Watanabe T, Asano N, Meng G, Yamashita K, Arai Y, Sakurai T, Kudo M, Fuss IJ, Kitani A, Shimosegawa T, Chiba T, Strober W
Mucosal Immunol   7 1312-1325   2014   [Refereed]
Stress response protein Cirp links inflammation and tumorigenesis in colitis-associated cancer
Sakurai T, Kashida H, Watanabe T, Hagiwara S, Mizushima T, Iijima H, Nishida N, Higashitsuji H, Fujita J, Kudo M
Cancer Res   74 6119-6128   2014   [Refereed]
Dynamic changes of the inflammation based index (IBI) predict mortality following chemoembolization for hepatocellular carcinoma: a prospective study
Pinato DJ, Karamanakos G, Arizumi T, Adjogatse D, Kim YW, Kudo M, Jang JW, Sharma R
Aliment Pharm Ther   40 1270-1281   2014   [Refereed]
Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: a randomized phase 3 trial
Kudo M*, Han G, Finn RS, Poon RTP, Blanc JF, Yan L, Yang J, Lu L, Tak WY, Yu X, Lee JH, Lin SM, Wu C, Tanwandee T, Shao G, Walters IB, Cruz CD, poulart V, Wang JH
Hepatology   60 1697-1707   2014   [Refereed]
Accuracy of real-time tissue elastography for the evaluation of hepatic fibrosis in patients with chronic hepatitis B: a prospective multicenter study
Wu T, Ren J, Cong SZ, Meng FK, Yang H, Luo Y, Lin HJ, Sun Y, Wang XY, Pei SF, Zheng Y, He Y, Chen Y, Hu Y, Yang N, Li P, Kudo M, Zheng RQ
Digest Dis   32 791-799   2014   [Refereed]
Clinical features of vascular disorders associated with chronic hepatitis virus infection
Nishida N, Kudo M
Digest Dis   32 786-790   2014   [Refereed]
Identification of epigenetically inactivated genes in human hepatocellular carcinoma by integrative analyses of methylation profiling and pharmacological unmasking
Nishida N, Chishina H, Arizumi T, Takita M, Kitai S, Yada N, Hagiwara S, Inoue T, Minami Y, Ueshima K, Sakurai T, Kudo M
Digest Dis   32 740-746   2014   [Refereed]
Decreased blood flow after sorafenib administration is an imaging biomarker to predict overall survival in patients with advanced hepatocellular carcinoma
Arizumi T, Ueshima K, Chishina H, Kono M, Takita M, Kitai S, Inoue T, Yada N, Hagiwara S, Minami Y, Sakurai T, Nishida N, Kudo M
Digest Dis   32 733-739   2014   [Refereed]
Validation of three staging systems for hepatocellular carcinoma (JIS score, biomarker-combined JIS score, and BCLC system) in 4,649 cases from a Japanese nationwide survey
Kitai S, Kudo M*, Izumi N, Kaneko S, Ku Y, Kokudo N, Sakamoto M, Takayama T, Nakashima O, Kadoya M, Matsuyama Y, Matsunaga T, for the Liver Cancer Study Group of Japan
Digest Dis   32 717-724   2014   [Refereed]
Duration of stable disease is associated with overall survival in patients with advanced hepatocellular carcinoma treated with sorafenib
Arizumi T, Ueshima K, Chishina H, Kono M, Takita M, Kitai S, Inoue T, Yada N, Hagiwara S, Minami Y, Sakurai T, Nishida N, Kudo M
Digest Dis   32 705-710   2014   [Refereed]
Ultrasound fusion imaging of hepatocellular carcinoma: a review of current evidence
Minami Y, Kudo M
Diegst Dis   32 690-695   2014   [Refereed]
Radiofrequency ablation for hepatocellular carcinoma measuring 2 cm or smaller: Results and risk factors for local recurrence
Kono M, Inoue T, Kudo M*, Chishina H, Arizumi T, Takita M, Kitai S, Yada N, Hagiwara S, Minami Y, Ueshima K, Nishida N, Murakami T
Digest Dis   32 670-677   2014   [Refereed]
Genome-wide profiling of DNA methylation and tumor progression in human hepatocellular carcinoma
Nishida N, Nishimura T, Nakai T, Chishina H, Arizumi T, Takita M, Kitai S, Yada N, Hagiwara S, Inoue T, Minami Y, Ueshima K, Sakurai T, Kudo M
Digest Dis   32 658-663   2014   [Refereed]
Emerging strategies for the management of hepatocellular carcinoma
Masatoshi Kudo
Digest Dis   32 655-657   2014   [Refereed][Invited]
Current treatment status of polycystic liver disease in Japan.
Ogawa K, Fukunaga K, Takeuchi T, Kawagishi N, Ubara Y, Kudo M, Ohkohchi N
Hepatol Res   44 1110-1118   2014   [Refereed]
Endoscopic ultrasonography-guided gallbladder drainage procedures: is the glass half-full or half-empty?
Kitano M, Kamata K, Kudo M
Digest Endosc   26 636-637   2014   [Refereed]
Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: The EVOLVE-1 randomized clinical trial
Zhu AX, Kudo M, Assenat E, Cattan S, Kang YK, Lim HY, Poon RTP, Blanc JF, Vogel A, Chen CL, Dorval E, Radosavljevic MPR, Santoro A, Daniele B, Furuse J, Jappe A, Perraud K, Anak O, Sellami DB, Chen LT
J Am Med Assoc (JAMA)   312 57-67   2014   [Refereed]
Homozygous deletion of the activin A receptor, type IB gene is associated with an aggressive cancer phenotype in pancreatic cancer
Togashi Y, Sakamoto H, Hayashi H, Terashima M, Velasco Ma, Fujita Y, Kodera Y, Sakai K, Tomida S, Kitano M, Kudo M, Nishio K
Mol Cancer   13 126-136   2014   [Refereed]
ART score for repeated transarterial chemoembolization in patients with hepatocellular carcinoma
Kudo M*, Arizumi T, Ueshima K
Hepatology   59 2424-2425   2014   [Refereed]
Contrast-enhanced endoscopic ultrasound
Kitano M, Sakamorto H, Kudo M
Digest Endosc   26 79-85   2014   [Refereed]
JSH cnsensus-based clinical practice guidelines for the management of hepatocellular carcinoma: 2014 update by the Liver Cancer Study Group of Japan
Kudo M*, Matsui O, Izumi N, Iijima H, Kadoya M, Imai Y, Okusaka T, Miyayama S, Tsuchiya K, Ueshima K, Hiraoka A, Ikeda M, Ogasawara S, Yamashita T, Minami T, Yamakado K, on behalf of the Liver Cancer Study Group of Japan
Liver Cancer   3 458-468   2014   [Refereed]
Alteration of epigenetic profile in human hepatocellular carcinoma and its clinical implications
Nishida N, Kudo M
Liver Cancer   3 417-427   2014   [Refereed]
Biomarkers and personalized sorafenib therapy
Masatoshi Kudo
Liver Cancer   3 399-404   2014   [Refereed]
Prognostic imapct of spontaneous tumor rupture in patients with hepatocellular carcinoma: an analysis of 1,160 cases from a nationwide survey
Aoki T, Kokudo N, Matsuyama Y, Izumi N, Ichida T, Kudo M, Ku Y, Sakamoto M, Nakashima O, Matsui O, Makuuchi M, for the Liver Cancer Study Group of Japan
Ann Surg   259 532-542   2014   [Refereed]
Serum amyloid A and C-reactive protein positive nodule in alcoholic liver cirrhosis, hard to make definite diagnosis
Kim SR, Kondo F, Otono Y, Imoto S, Ando K, Hirakawa M, Fukuda K, Sakaki M, Kim SK, Komaki T, Tsuchida S, Kobayashi S, Matsuoka T, Kudo M
Hepatol Res   44 584-590   2014   [Refereed]
Nationwide survey in Japan regarding splenectomy/partial splenic embolization for interferon treatment targeting hepatitis C virus-related chronic liver disease in patients with low platelet count.
Ikeda N, Imanishi H, Aizawa N, Tanaka H, Iwata Y, Enomoto H, Siato M, Iijima H, Iimuro Y, Fujimoto J, Yamamoto S, Hirota S, Kudo M, Arii S, Nishiguchi S
Hepato Res   44 829-836   2014   [Refereed]
Prediction of incidence risk of hepatocellular carcinoma by ultrasound elastography
Kudo M
Liver Cancer   3 1-5   2014
Unique association between global DNA ypomethylation and hromosomal alterations in human hepatocellular carcinoma
Nishida N, Kudo M, Nishimura T, Arizumi T, Takita M, Kitai S, Yada N, Hagiwara S, Inoue T, Minami Y, Ueshima K, Sakurai T, Yokomichi N, Nagasaka T, Goel A
Plos One   8 e72312   2013   [Refereed]
Brivanib in patients with advanced hepatocellular carcinoma who failed or were intolerant to sorafenib: or for whom sorafenib faied results from the randomized phase 3 BRISK-PS study
Llovet JM, Decaens T, Raoul JL, Boucher E, Kudo M, Chang C, Kang YK, Assenat E, Lim HY, Boige V, Mathurin P, Fartoux L, Lin DY, Bruix J, Poon RT, Sherman M, Blanc, JF, Finn RS, Tak WY, Chao Y, Ezzeddine R, Liu D, Walters I, Park JW
J Clin Oncol   31 3509-3516   2013
Diagnostic value of endoscopic ultrasound-guided directional eFLOW in solid pancreatic lesions
Das K, Kudo M, Kitano M, Sakamoto H, Komaki T, Takagi T, Yamao K
J Med Ultrason   40 211-218   2013
Challenges of clinical research on hepatocellular carcinoma
Kudo M*, Kitano M, Sakurai T, Nishida N
Digest Dis   33 780-790   [Refereed]

Misc

 
KUDO Masatoshi
109(8) 1327-1334   Aug 2012
ARIZUMI Tadaaki, UESHIMA Kazuomi, TAKEDA Haruhiko, OSAKI Yukio, HAGIWARA Satoru, INOUE Tatsuo, KITAI Satoshi, YADA Norihisa, SAKURAI Toshiharu, NISHIDA Naoshi, KUDO Masatoshi
Kanzo   53(6) 344-347   Jun 2012
Response Evaluation Criteria In Solid Tumor version 1.1 (RECIST1.1), modified RECIST (mRECIST) and Response Evaluation Criteria In Cancer of the Liver (RECICL) are frequently used as a response evaluation criteria for hepatocellular carcinoma. The...
ARIZUMI Tadaaki, UESHIMA Kazuomi, HAYAISHI Sousuke, TAKITA Masahiro, KITAI Satoshi, INOUE Tatsuo, YADA Norihisa, HAGIWARA Satoru, MINAMI Yasunori, SAKURAI Toshiharu, NISHIDA Naoshi, KUDO Masatoshi
Kanzo   53(6) 348-350   Jun 2012
【PURPOSE】 Sorafenib is a molecularly-targeted drug, which have been proven survival benefit for advanced hepatocellular carcinoma (HCC). Because of the unique side effects of sorafenib such as hand-foot skin reaction (HFSR), the administration of ...
INUZUKA Tadashi, OSAKI Yukio, MATSUDA Fumihiro, SAKAMOTO Azusa, HATAMARU Keiichi, HENMI Shinichiro, ISHIKAWA Tetsuro, SAITO Sumio, NISHIKAWA Hiroki, KITA Ryuichi, OKABE Yoshihiro, KIMURA Toru, WAKASA Tomoko, HAGIWARA Satoru, KUDO Masatoshi
Kanzo   53(1) 42-47   Jan 2012
A 65-year-old Japanese male with chronic hepatitis B (CH-B) diagnosed in December 2008 was referred to our department in July 2009. He started combination therapy with peginterferon alfa-2b (80 μg/week) and entecavir (0.5 mg/day) for 48 weeks from...
KUDO Masatoshi
Nippon Shokakibyo Gakkai Zasshi   109(8) 1327-1334   2012

Books etc

 
Liver Cancer, Okuda K and Tabor E, eds, Ultrasound Diagnosis
Churchill Livingstone, London   1997   
"Diagnosis and Treatment of Hepatocellular Carcinoma", Livraghi T, Makuuchi M, Buscarini, eds, Scintigraphy
Greenwich Medical Media Limited, London, UK   1997   
"Hepatology in the 21st Century: Diagnosis and Therapy." Tanikawa K, Kojiro M, Gollan J, eds, Advances in diagnostic imaging of hepatocellular carcinoma
IASL, APASL, and JSH JOINT POST GRADUATE TEXTBOOK, IASL Publ, Fukuoka   2000   
In Dynamic Study of Efferent Tumor Blood Fow, Itai Y, Miura Y, eds, Color Doppler observation of efferent blood flow in liver tumors
BRACCO, Italy   2000   

Conference Activities & Talks

 
Phase 1/2 study of durvalumab and tremelimumab as monotherapy and in combination in patients with unresectable hepatocellular carcinoma (HCC)
Abou-Alfa GK, Sangro B, Morse M, Zhu AX, Kim RD, Cheng AL, Kudo M, Kang YK, Chan SL, Antal J, Boice J, Xiao F, Morris SR, Bendell J, 022 Study Group
52nd American Society of Clinical Oncologys Annual Meeting 2016 (ASCO 2016)   5 Jun 2016   
Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion: A Japanese nationwide survey
Kokudo T, Hasegawa K, Matsuyama Y, Takayama T, Izumi N, Kadoya M, Kudo M, Ku Y, Sakamoto M, Nakashima O, Kaneko S, Kokudo N
52nd American Society of Clinical Oncologys Annual Meeting 2016 (ASCO 2016)   4 Jun 2016   
A randomized, double-blind, placebo-controlled phase III study of ramucirumab versus placebo as second-line treatment in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein following first-line sorafenib (REACH-2)
Zhu AX, Galle PR, Kudo M, Finn RS, Yang L, Abada P, Llovet JM
52nd American Society of Clinical Oncologys Annual Meeting 2016 (ASCO 2016)   4 Jun 2016   
Safety and antitumor activity of Nivolumab (nivo) in patients (pts) with advanced hepatocellular carcinoma (HCC): interim analysis of dose-expansion cohorts from the phase 1/2 checkmate 040 study
Sangro B, Melero I, Yau TC, Hsu C, Kudo M, Crocenzi TS, Kim TY, Choo SP, Trojan J, Meyer T, Kang YK, Anderson J、Dela Cruz C, Lang L, Neely J, El-Khoueiry AB
52nd American Society of Clinical Oncologys Annual Meeting 2016 (ASCO 2016)   4 Jun 2016   
EUS-guided interventions for walled-off pancreatic necrosis: clinical outcomes of a step-up approach and risk factors for failed endoscopic treatment. シンポジウム 消化器Joint「Role of EUS in diagnosis and treatment of digestive diseases」
Minaga K, Kitano M, Imai H, Yamao K, Kamata K, Miyata T, Matsuda T, Omoto S, Kadosaka K, Kudo M
日本超音波医学会第89回学術集会, 第36回日本乳腺甲状腺超音波医学会学術集会, アジア超音波医学生物学会第12回学術集会(AFSUMB), アジア造影超音波会議第8回学術集会(ACUCI)(Ultrasonic Week 2016)   28 May 2016   
Utility of endoscopic ultrasonography for follow-up of IPMN. シンポジウム 消化器Joint「Role of EUS in diagnosis and treatment of digestive diseases」
Kamata K, Kitano M, Kudo M
日本超音波医学会第89回学術集会, 第36回日本乳腺甲状腺超音波医学会学術集会, アジア超音波医学生物学会第12回学術集会(AFSUMB), アジア造影超音波会議第8回学術集会(ACUCI)(Ultrasonic Week 2016)   28 May 2016   
An objective model to optimize treatment decisions in advanced hepatocellular carcinoma after sorafenib failure: the SORFA score
Pinato DJ, Yen C, Arizumi T, Giarda P, Howell J, Ramaswami R, Burlone ME, Kudo M, Pirisi M, Sharma R
The International Liver Congress 2016   16 Apr 2016   
Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: Analysis of REACH patients by albumin-bilirubin (ALBI) grade
Blanc JF, Chan SL, Park JO, Ryoo BY, Yen CJ, Kudo M, Poon R, Pastorelli D, Baran A, Pfiffer T, Okusaka T, Kubackova K, Trojan J, Sastre J, Chau I, Abada P, Chang SC, Yang L, Zhu A
The International Liver Congress 2016   16 Apr 2016   
Prospective randomized controlled phase III trial comparing the efficacy of sorafenib versus sorafenib in combination with low-dose cisplatine/fluorouracil hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma
Kudo M, Ueshima K, Yokosuka O, Obi S, Izumi N, Aikata H, Nagano H, Hatano E, Sasaki Y, Hino K, Kumada T, Yamamoto K, Imai Y, Iwadou S, Ogawa C, Okusaka T, Arai Y, Kanai F, Akazawa K, and SILIUS Study Group
The International Liver Congress 2016   16 Apr 2016   
Invited Lecture “Hepatocellular cancer drug development” [Invited]
Masatoshi Kudo
8th Annual Asian Oncology Summit (AOS 2016)   4 Mar 2016   
Practice patterns, sorafenib dosing and safety in Asian hepatocellular carcinoma patients in GIDEON
Kudo M, Venook A, Lencioni R, Ye SL, Nakajima K, Marrero J
25th Conference of the Asian Pacific Association for the Study of the Liver (APASL)   23 Feb 2016   
Regional differences in practice patterns among countries, Luncheon Symposium “New light on the integration of evidence into practice” [Invited]
Masatoshi Kudo
25th Conference of the Asian Pacific Association for the Study of the Liver (APASL)   23 Feb 2016   
Biomarker and Imaging Diagnosis of HCC. Symposium 11 “Update of HCC Treatment”
Masatoshi Kudo
25th Conference of the Asian Pacific Association for the Study of the Liver (APASL)   23 Feb 2016   
Invited Lecture “Non-Curative Treatment (TACE/Sorafenib) of HCC” [Invited]
Masatoshi Kudo
25th Conference of the Asian Pacific Association for the Study of the Liver (APASL)   23 Feb 2016   
Regional Differences in the Use of Transarterial Chemoembolization (TACE) in HCC: Interim Analysis of OPTIMIS, an International Observational Study Assessing the Use of Sorafenib After TACE
Lee HC, Cheng AL, Raoul JL, Peck-Radosavljevic M, Nakajima K, Kudo M, on behalf of the OPTIMIS Investigators
25th Conference of the Asian Pacific Association for the Study of the Liver (APASL)   23 Feb 2016   
Regional differences in efficacy/safety/biomarkers in a randomised study of axitinib in 2nd line patients (pts) with advanced hepatocellular carcinoma (HCC)
Masatoshi Kudo
American Society of Clinical Oncology, 2016 Gastrointestinal Cancers Symposium (ASCO GI 2016)   22 Jan 2016   
Identification of a high-response patient population to S-1 via predictive enrichment strategy analysis of the S-CUBE phase III trial
Kudo M, Okusaka T, Kaneko S, Furuse J, Takeuchi M, Fang X, Date Y, Takeuchi M
American Society of Clinical Oncology, 2016 Gastrointestinal Cancers Symposium (ASCO GI 2016)   22 Jan 2016   
A randomized, double-blind, placebo-controlled phase III study of ramucirumab versus placebo as second-line treatment in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein following first-line sorafenib (REACH-2)
Zhu A, Galle PR, Kudo M, Finn RS, Yang L, Abada P, Chang SC, Llovet JM
American Society of Clinical Oncology, 2016 Gastrointestinal Cancers Symposium (ASCO GI 2016)   22 Jan 2016   
Usefulness of serum procalcitonin for diagnosis of acute pancreatitis
Omoto S, Kitano M, Sakamoto H, Imai H, Yamao K, Kamata K, Miyata T, Minaga K, Kadosaka K, Kudo M
Asian Pacific Digestive Week (APDW 2016)   3 Dec 2015   
The analysis of three cases that gastrointestinal bezoars have history of gastrointestinal surgery
Okamoto K, Matsui S, Tanaka R, Yamada M, Adachi T, Takayama M, Mine H, Nagai T, Okazaki Y, Komeda Y, Asakuma Y, Sakurai T, Kashida H, Kudo M
Asian Pacific Digestive Week (APDW 2016)   3 Dec 2015   
Treatment of colorectal LST: focus on EMR techniques
Komeda Y, Kashida H, Sakurai T, Asakuma Y, Okazaki Y, Nagai T, Mine H, Adachi T, Tanaka R, Yamada M, Kono M, Okamoto K, Matsui S, Kudo M
Asian Pacific Digestive Week (APDW 2016)   3 Dec 2015   
A case of endoscopic mucosal resection for gastric perineurioma
Kono M, Matsui S, Okamoto K, Yamada M, Tanaka R, Adachi T, Mine H, Nagai T, Okazaki Y, Komeda Y, Asakuma Y, Sakurai T, Kashida H, Kudo M
Asian Pacific Digestive Week (APDW 2016)   3 Dec 2015   
Endoscopic resection for rectal nets (neuroendocrine tumors): EMR-C (EMR using a cap), EMR-L (EMR with a ligation device), or conventional EMR (EMR)
Yamada M, Kashida H, Komeda Y, Okamoto K, Kono M, Tanaka R, Adachi T, Mine H, Nagai T, Okazaki Y, Asakuma Y, Sakurai T, Matsui S, Kudo M
Asian Pacific Digestive Week (APDW 2016)   3 Dec 2015   
Classification of tumors based on the integrated profile of genetic and epigenetic alterations and the biological behavior of human hepatocellular carcinoma
Nishida N, Kaido T, Kudo M
66th Annual Meeting, American Association for the Study of Liver Diseases (AASLD 2015)   17 Nov 2015   
PALBI-an objective score based on platelets, albumin & Bilirubin Stratifies HCC patients undergoing resection & ablation better than Child’s classification
Roayaie S, Jibara G, Berhane S, Tabrizian P, Park JW, Yang J, Yan L, Han G, Izzo F, Chen M, Blanc JF, Kudo M, Roberts LR, Sherman M, Johnson P
66th Annual Meeting, American Association for the Study of Liver Diseases (AASLD 2015)   14 Nov 2015   
Predictive factors for outcomes of through-the-scope gastroduodenal stenting in patients with gastric outlet obstruction; a large multicenter retrospective study in West Japan
Yamao K, Kitano M, Kayahara T, Ishida E, Minaga K, Yamashita Y, Nakajima J, Asada M, Okabe S, Chiba Y, Imai H, Kudo M
23rd United European Gastroenterology Week (UEGW 2015)   27 Oct 2015   
Evaluation of anti-migration properties of biliary covered self-expandable metal stents
Minaga K, Kitano M, Harwani Y, Imai H, Kamata K, Miyata T, Yamao K, Kadosaka K, Omoto S, Kudo M
23rd United European Gastroenterology Week (UEGW 2015)   26 Oct 2015   
Invited Lecture “Ultrasound fusion imaging of liver tumor: recent progress and clinical relevance” [Invited]
Masatoshi Kudo
IEEE International Ultrasonics Symposium   23 Oct 2015   
EUS guided biliary drainage for treatment of biliary obstruction. International Session (Panel Discussion) 2 “Strategy of treatment for biliary stenosis”
Imai H, Kitano M, Kudo M
第90回日本消化器内視鏡学会総会   10 Oct 2015   
Discussant, International Session (Symposium) 1 “Hepatocellular carcinoma: molecular approaches for diagnosis, prognosis, and therapy” [Invited]
Masatoshi Kudo
8 Oct 2015   
Tumor characteristics and genetic and epigenetic profile of human hepatocellular carcinoma. International Session (Symposium) 1 “Hepatocellular carcinoma: molecular approaches for diagnosis, prognosis, and therapy”
Nishida N, Kudo M
8 Oct 2015   
Invited Lecture “Hepatologists’ perspectives on EOB-MRI: Pre-& post-operative evaluation in malignant lesions” [Invited]
Masatoshi Kudo
Asila Pacific Liver Imaging Symposium (APLIS)   17 Sep 2015   
Invited Lecture; Luncheon Satellite Symposium “Treatment strategies to optimize outcome and experience of patients with HCC” [Invited]
Masatoshi Kudo
The Liver Week 2015   12 Sep 2015   
KLCSG & LCSGJ Joint Symposium “HCC nationwide surveillance and out come in Japan” [Invited]
Masatoshi Kudo
The Liver Week 2015   12 Sep 2015   
Special Lecture 2”The evolution of HCC treatment” [Invited]
Masatoshi Kudo
The Liver Week 2015   11 Sep 2015   
Chair: General Session 2 “Molecular Pathogenesis of Liver Cancer II” [Invited]
Masatoshi Kudo
International Liver Cancer Association 9th Annual Conference (ILCA) 2015   4 Sep 2015   
Ramucirumab (RAM) as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) following first-line therapy with sorafenib in the randomized Phase III REACH study: analysis ofα-fetoprotein (AFP) kinetics during treatment
Chau I, Park JO, Ryoo BY, Yen CJ, Poon R, Pastorelli D, Blanc JF, Kudo M, Eduardo T, Pfiffer F, Hatano E, Chung HC, Kubackova K, Phelip JM, Brandi G, Ohkawa S, Li CP, Okusaka T, Yang L, Abada PB, Zhu AX
European Cancer Congress 2015 (18th ECCO-40th ESMO)   Sep 2015   
Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: Japanese subgroup analysis of the phase III REACH trial.
Kudo M, Hatano E, Okusaka T, Ohkawa S, Fujii H, Masumoto A, Furuse J, Wada Y, Ishii H, Obi S, Arai K, Kawazoe S, Yokosuka O, Ikeda M, Ukai K, Morita S, Asou H, Abada PB, Yang L, Zhu AX
9th Annual Conference International Liver Cancer Association (ILCA)   Sep 2015   
Invited Lecture “Assessing treatment effect and treatment failure: when to stop LRTs” [Invited]
Masatoshi Kudo
9th Annual Conference International Liver Cancer Association (ILCA)   Sep 2015   
State of Art Lecture “Benefit of early diagnosis of liver cancer with changed therapeutic paradigm in HCC” [Invited]
Masatoshi Kudo
23rd Annual Indian National Association for the Study of Liver (INASL) and Current Perspectives in Liver Diseases (CPLD)   2 Aug 2015   
Invited Lecture “Imaging in early HCC-MR advances” [Invited]
Masatoshi Kudo
23rd Annual Indian National Association for the Study of Liver (INASL) and Current Perspectives in Liver Diseases (CPLD)   1 Aug 2015   
Invited Lecture“HCC: early diagnosis impacts prognosis” [Invited]
Masatoshi Kudo
23rd Annual Indian National Association for the Study of Liver (INASL) and Current Perspectives in Liver Diseases (CPLD)   31 Jul 2015   
Invited Lecture“Molecular targeted therapy for HCC: current status and future perspectives” [Invited]
Masatoshi Kudo
23rd Annual Indian National Association for the Study of Liver (INASL) and Current Perspectives in Liver Diseases (CPLD)   31 Jul 2015   
Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): Japanese subgroup analysis of the phase III REACH trial
Ohkawa S, Okusaka T, Kudo M, Hatano E, Fujii H, Masumoto A, Furuse J, Wada Y, Ishii H, Obi S, Arai K, Kawazoe S, Yokosuka O, Ikeda M, Ukai K, Morita S, Asou H, Abada PB, Yang L, Zhu AX
The 13th Annual Meeting of Japanese Soceity of Medical Oncology   17 Jul 2015   
Activin signal in pancreatic cancer
Togashi Y, Sakamoto H, Kogita A, de Velasco M, Sakai K, Fujita Y, Tomida S, Kitano M, Kudo M, Nishio K
The 13th Annual Meeting of Japanese Soceity of Medical Oncology   17 Jul 2015   
Chair "Poster Session: Biliary Tract and Pancreatic Cancer 2 FOLFIRINOX(2)" [Invited]
Masatoshi Kudo
The 13th Annual Meeting of Japanese Society of Medical Oncology   16 Jul 2015   
Moderator and Commentator “Non-surgical treatment of HCC: achievement from Taiwan over the past quarter century” [Invited]
Masatoshi Kudo
Taiwan Association for the Study of the Liver 2015 (TASL)   12 Jul 2015   
Moderator and Commentator “Androgen pathway in the mechanisms of liver carcinogenesis and targets for future therapy” [Invited]
Masatoshi Kudo
Taiwan Association for the Study of the Liver 2015 (TASL)   12 Jul 2015   
Chari: Sponsored Seminar“Diagnostic Imaging with EOB-MRI for Malignancy Grade of HCC” [Invited]
Masatoshi Kudo
The 6th Asia-Pacific Primary Liver Cancer Expert Meeting   3 Jul 2015   
Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): Analysis of REACH pts by Child-Pugh (CP) score
Zhu AX, Baron AD, Malfertheiner P, Kudo M, Kawazoe S, Pezet D, Weissinger F, Brandi G, Barone C, Okusaka T, Wada Y, Park J, Ryoo B, Cho JY, Chung HC, Li C, Yen C, Lee K, Yang L, Chau I
Annual Meeting of American Society of Clinical Oncology (ASCO 2015)   1 Jun 2015   
Objective response by mRECIST to predict survival in hepatocellular carcinoma: A multivariate, time-dependent analysis from the phase III BRISK-PS study
Llovet JM, Park J, Torres F, Decaens T, Boucher E, Raoul J, Kudo M, Chang C, Boige V, Assenat E, Kang Y, Lim H, Walters I, Lencioni R
Annual Meeting of American Society of Clinical Oncology (ASCO 2015)   1 Jun 2015   
Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome (PFO) results from the phase 3 REACH study
Chau I, Peck-Radosavljevic M, Borg C, Malfertheiner P, Seitz J, Park J, Ryoo B, Yen C, Kudo M, Poon RT, Pastorelli D, Blanc J, Chung H, Baron AD, Okusaka T, Cui ZL, Girvan AC, Abada P, Yang L, Zhu AX
Annual Meeting of American Society of Clinical Oncology (ASCO 2015)   1 Jun 2015   
Sorafenib plus intra-arterial cisplatin versus sorafenib alone in patients with advanced hepatocellular carcinoma: A randomized phase II trial
Ikeda M, Shimizu S, Sato T, Morimoto M, Inaba Y, Kojima Y, Hagihara A, Kudo M, Nakamori S, Kaneko S, Sugimoto R, Tahara T, Ohmura T, Yasui K, Sato K, Ishii H, Furuse J, Okusaka T
Annual Meeting of American Society of Clinical Oncology (ASCO 2015)   1 Jun 2015   
Proposal of a new staging system for intrahepatic cholangiocarcinoma: Analysis of surgical patients from a nationwide survey of Liver Cancer Study Group of Japan
Sakamoto Y, Kokudo N, Matsuyama Y, Sakamoto M, Kadoya M, Kaneko S, Ku Y, Kudo M, Takayama T, Nakashima O, The Liver Cancer Study Group of Japan
Annual Meeting of American Society of Clinical Oncology (ASCO 2015)   1 Jun 2015   
A randomized, double-blind, placebo-controlled phase III study of S-1 in patients with sorafenib refractory advanced hepatocellular carcinoma (S-CUBE)
Kudo M, Moriguchi M, Numata K, Hidaka H, Tanaka H, Ikeda M, Kawazoe S, Ohkawa S, Sato Y, Okusaka T
Annual Meeting of American Society of Clinical Oncology (ASCO 2015)   1 Jun 2015   
Invited Lecture “HCC nationwide surveillance and outcome in Japan” [Invited]
Masatoshi Kudo
The Liver Week 2015   12 Sep 2015   
Invited Lecture “The evolution of HCC treatment” [Invited]
Masatoshi Kudo
The Liver Week 2015   11 Sep 2015   
Chairs: “KLCSG & JLCSG Joint Symposium” [Invited]
Masatoshi Kudo
The Liver Week 2015   12 Sep 2015   
Contrast-enhanced harmonic EUS for differential diagnosis of pancreatic tumors. International Video Session 2 “Advances and education of endoscopic diagnosis and treatment-biliary tract, pancreas-“
Kamata K, Kitano M, Kudo M
第89回日本消化器内視鏡学会総会   29 May 2015   
An international observational study to assess the use of sorafenib after transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC): OPTIMIS
Peck-Radosavljevic M, Raoul JL, Lee HC, Kudo M, Nakajima K, Cheng AL
50th Annual Meeting of the European Association for the Study of the Liver (EASL 2015)   24 Apr 2015   
Combined sequential use of HAP and ART scores to predict transarterial chemoembolization failure in hepatocellular carcinoma: a multicenter comparative study
Pinato DJ, Arizumi T, Jang JW, Allara E, Suppiah P, Smirne C, Grossi G, Pirisi M, Kudo M, Sharma R
50th Annual Meeting of the European Association for the Study of the Liver, (EASL 2015)   24 Apr 2015   
Invited Lecture “Surveillance, treatment and outcome of HCC in Japan” [Invited]
Masatoshi Kudo
Joint Workshop EASL-JSH, 50th International Liver Congress of the European Association for the Study of the Liver (EASL)   25 Apr 2015   
GIDEON (Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of Its Treatment with Sorafenib): A retrospective analysis of prognostic factors for survival
Bronowicki JP, Kudo M, Lencioni R, Chen XP, Dagher L, Furuse J, Geschwind JFH, de Guevara LL, Papandreou C, Sanyal AJ, Takayama T, Yoon SK, Nakajima K, Ye SL, Marrero JA
50th Annual Meeting of the European Association for the Study of the Liver, (EASL 2015)   24 Apr 2015   
Activin signal promotes cancer progression and is involved in cachexia in a subset of pancreatic cancer
Togashi Y, Kogita A, Sakamoto H, Hayashi H, Terashima M, de Velasco MA, Sakai K, Fujita Y, Tomida S, Kitano M, Kudo M, Nishio K
American Association for Cancer Research Annual Meeting (AACR 2015)   21 Apr 2015   
Axitinib safety and pharmacokinetics in Child-Pugh A and Child-Pugh B patients with advanced hepatocellular cancer
Kang YK, Seery TE, Kato M, Chakrabarti D, Valota O, Chen Y, Jie T, Pithavala Y, Kudo M
American Association for Cancer Research Annual Meeting (AACR 2015)   19 Apr 2015   
Invited Lecture “WFUMB Guidelines” [Invited]
Masatoshi Kudo
American Institute of Ultrasound in Medicine Annual Convention (AIUM 2015/WFUMB 2015)   21 Mar 2015   
Invited Lecture “Liver strain” [Invited]
Masatoshi Kudo
American Institute of Ultrasound in Medicine Annual Convention (AIUM 2015/WFUMB 2015)   21 Mar 2015   
Multicenter Observational Study of Reactivation of Hepatitis B Virus Caused by Chemotherapy with Sorafenib
Furuse J, Ikeda M, Kondo S, Kudo M, Nadano S, Osaki Y, Kumada T, Ohkawa K, Mizokami M
24th Conference of APASL   14 Mar 2015   
Multicenter observational study of reactivation of hepatitis B virus caused by chemotherapy for solid tumors
Furuse J, Ikeda M, Kondo S, Kudo M, Nadano S, Osaki Y, Kumada T, Ohkawa K, Mizokami M
24th Conference of APASL   14 Mar 2015   
Invited Lecture “Recent advances in therapy for advanced hepatocellular carcinoma” [Invited]
Masatoshi Kudo
The 24th Annual Conference of Asian Pacific Association for the Study of the Liver (APASL)   13 Mar 2015   
Invited Lecture “The Eastern point of view” [Invited]
Masatoshi Kudo
Eastern & Western Association Liver Tumors (1st ewalt)   22 Jan 2015   
Invited Lecture “Molecular targeted therapy for HCC: Past, present and future perspective” [Invited]
Masatoshi Kudo
24th World Congress of the International Association of Surgeons, Gastroenterologists and Oncologists (IASGO 2014)   6 Dec 2014   
Endoscopic resection for rectal nets (neuroendocrine tumors): EMR-C (EMR using a cap), EMR-L (EMR with a ligation device), or conventional EMR
Yamada M, Kashida H, Tanaka R, Adachi T, Mine H, Takayama M, Okazaki Y, Nagata Y, Nagai T, Kawasaki M, Komeda N, Asakuma Y, Sakurai T, Matsui S, Kudo M
Asian Pacific Digetive Week (APDW 2014)   23 Nov 2014   
Small-intestinal mucosal injury induced by non-steroidal anti-inflammatory drugs or antiplatelet agents in our hospital
Nagai T, Tanaka R, Yamada M, Adachi T, Takayama M, Mine H, Okazaki Y, Komeda Y, Asakuma Y, Sakurai T, Matsui S, Kashida H, Kudo M
Asian Pacific Digetive Week (APDW 2014)   23 Nov 2014   
The clinical characteristics and treatment of eosinophilic esophagitis
Matsui S, Kashida H, Kawasaki M, Asakuma Y, Sakurai T, Kudo M
Asian Pacific Digetive Week (APDW 2014)   23 Nov 2014   
Two cases of gastric amyloidosis
Matsui S, Kashida H, Okamoto K, Asakuma Y, Sakurai T, Kudo M
Asian Pacific Digetive Week (APDW 2014)   23 Nov 2014   
Colorectal endoscopic submucosal dissection is useful and safe
Kashida H, Adachi T, Komeda Y, Sakurai T, Asakuma Y, Takayama M, Mine H, Kudo M
Asian Pacific Digetive Week (APDW 2014)   23 Nov 2014   
Comparison of Japanese primary and secondary regimen of Helicobacter pylori eradication
Adachi T, Tanaka R, Yamada M, Takayama M, Mine H, Nagai T, Kawasaki M, Asakuma Y, Okazaki Y, Komeda Y, Sakurai T, Matsui S, Kashida H, Kudo M
Asian Pacific Digetive Week (APDW 2014)   23 Nov 2014   
The usefulness of single-balloon endoscopy for the small bowel lesions
Adachi T, Tanaka R, Yamada M, Takayama M, Mine H, Nagai T, Kawasaki M, Asakuma Y, Okazaki Y, Komeda Y, Sakurai T, Matsui S, Kashida H, Kudo M
Asian Pacific Digetive Week (APDW 2014)   22 Nov 2014   
Chair "Session 5: Hepatocellular carcinoma, basic and therapy" [Invited]
Masatoshi Kudo
The 11th JSH Single Topic Conference   21 Nov 2014   
Involvement of stress response protein crip in refractory inflammatory bowel diseases and colitis-associated cancer. Symposium 1 “Cancer prevention and early diagnosis”
Sakurai T, Kashida H, Kudo M
The 25th Annual Meeting of the Japanese Society for Gastroenterological Carcinogenesis   13 Nov 2014   
How is BCLC stage C HCC treated in real-word practice and what outcomes are obtained?
Roayaie S, Jibara G, Tabrizian P, Park JW, Yang J, Yan L, Han G, Izzo F, Chen M, Blanc JF, Johnson P, Kudo M, Roberts LR, Sherman M
65th Annual Meeting, American Association for the Study of Liver Diseases (AASLD2014)   10 Nov 2014   
Early response prediction of hepatocellular carcinoma to conventional transcatheter chemoembolization using intraprocedual plain cone-beam CT
Minami Y, Kudo M
65th Annual Meeting, American Association for the Study of Liver Diseases (AASLD2014)   10 Nov 2014   
Pathological feature, oxidative DNA damage and epigenetic alteration of tumor suppressor genes in nonalcoholic fatty liver disease
Nishida N, Yada N, Chishina H, Arizumi T, Takita M, Kitai S, Inoue T, Hagiwara S, Minami Y, Ueshima K, Sakurai T, Kudo M
65th Annual Meeting, American Association for the Study of Liver Diseases (AASLD2014)   9 Nov 2014   
Invited Lecture “Interventaional and contrast EUS for pancreatobiliary disease” [Invited]
Masatoshi Kudo
The 11the Congress of the Asian Federation of Societies for Ultrasound and Biology (AFSUMB 2014)   31 Oct 2014   
Invited Lecture “Fusion imaging for treatment guidance of hepatic tumours” [Invited]
Masatoshi Kudo
The 11the Congress of the Asian Federation of Societies for Ultrasound and Biology (AFSUMB 2014)   31 Oct 2014   
Predictive factors for pain relief after EUS-guided neurolysis in patietnts suffering from upper abdominal cancer pain. International Session (Symposium) 6 “EUS-guided therapy: current status and future directions”
Kitano M, Sakamoto H, Kudo M
Japan Digestive Disease Week 2014 (JDDW)   26 Oct 2014   
Ramucirumab (RAM; IMC-1121B) as Second-Line Treatment in Patients with Advanced Hepatocellular Carcinoma Following First-Line Therapy With Sorafenib: Results from the Randomized Phase III REACH Study [Invited]
Zhu A, Ryoo BY, Yen CJ, Kudo M, Poon R, Pastorelli D, Blanc JF, Chung H, Baron A, Pfiffer T, Okusaka T, Kubackova K, Trojan J, Sastre J, Chau I, Chang SC, Abada P, Yang L, Schwartz J, Park J
European Society for Medical Oncology Congress (ESMO 2014)   28 Sep 2014   
Chair “e-poster viewing tour and networking break” [Invited]
Masatoshi Kudo
8th ILCA Annual Conference   6 Sep 2014   
STORM: A phase III, randomized, double-blind, placebo-controlled trial of adjuvant sorafenib after resection or ablation to prevent recurrence of hepatocellular carcinoma
Llovet JM, Takayama T, Mazzaferro V, Chau GY, Yang J, Kudo M, Cai J, Poon RT, Han KH, Tak WY, Lee HC, Song T, Roaayaie S, Bolondi L, Lee KS, Makuuchi M, Souza F, Le Berre MA, Meinhardt G, Bruix J, on behalf of the STORM investigators
8th Annual Conference, International Liver Cancer Association (ILCA 2014)   6 Sep 2014   
Newly simulated virtual ultrasound sonography software before RFA
Ogawa C, Kudo M
8th Annual Conference, International Liver Cancer Association (ILCA 2014)   6 Sep 2014   
Proposals for improvement of the AJCC/UICC and Japanese staging systems for intrahepatic cholangiocarcinoma in review of the Japanese nationwide database
Sakamoto Y, Kokudo N, Matsuyama Y, Izumi N, Ichida T, Ku Y, Kudo M, Sakamoto M, Takayama T, Nakashima O, Matsui O
8th Annual Conference, International Liver Cancer Association (ILCA 2014)   6 Sep 2014   
Early response prediction of hepatocellular carcinoma to conventional transcatheter chemoembolization using intraprocedual plain cone-beam CT
Minami Y, Murakami T, Kudo M
8th Annual Conference, International Liver Cancer Association (ILCA 2014)   6 Sep 2014   
How is BCLC stage C HCC treated in real-word practice and what outcomes are obtained? Answers from the Bridge database
Roayaie S, Jibara G, Tabrizian P, Park JW, Yang J, Yan L, Han G, Izzo F, Chen M, Blanc JF, Johnson P, Kudo M, Roberts LR, Sherman M
8th Annual Conference, International Liver Cancer Association (ILCA 2014)   6 Sep 2014   
Tumor response to transarterial chemoembolization in unresectable hepatocellular carcinoma patients in clinical practice: findings from the GIDEON database
Kudo M, Marrero J, Lencioni R, Nakajima K, Ye SL
8th Annual Conference, International Liver Cancer Association (ILCA 2014)   6 Sep 2014   
Randomized phase II trial of intravenous RO5137382/GC33 at 1600 mg every other week and placebo in previously treated patients with unresectable advanced hepatocellular carcinoma (HCC) (NCT01507168)
Kudo M, Yen CJ, Daniele B, Merle P, Park JW, Ross P, Peron JM, Ebert O, Chan S, Poon TP, Colombo M, Okusaka T, Ryoo BY, Minguez B, Tanaka T, Ohtomo T, Rutman O, Chen YC, Lee R, Abou-Alfa GK
8th Annual Conference, International Liver Cancer Association (ILCA 2014)   6 Sep 2014   
Invited Lecture “Surveillance, treatment and outcome of HCC in Japan”, ILCA Symposium 3 “Noevel opportunities for treatment in HCC” [Invited]
Masatoshi Kudo
The 8th Annual Conference, International Liver Cancer Association (ILCA)   6 Sep 2014   
B-mode ultrasonography versus contrast-enhanced ultrasonography for surveillance of hepatocellular carcinoma: a prospective multicenter randomized controlled trial (Nct01507168)
Kudo M, Ueshima K, Osaki Y, Hirooka M, Imai Y, Aso K, Numata K, Ichinose M, Kumada T, Izumi N, Sumino Y, Akazawa K
8th Annual Conference, International Liver Cancer Association (ILCA 2014)   6 Sep 2014   
Chair "Symposium 2 “Treatment strategy for advanced stage hepatocellular carcinoma after approval of sorafenib” [Invited]
Masatoshi Kudo
The 12th Annual Meeting of Japanese Society of Medical Oncology   17 Jul 2014   
Chair "Session 10 “APPLE consensus workshop: searching consensus for controversies” [Invited]
Masatoshi Kudo
The 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)   13 Jul 2014